Showing posts with label LSD. Show all posts
Showing posts with label LSD. Show all posts

Sunday, August 18, 2013

LSD Mutates Into NBOMe


What’s on that blotter?

It is a darkly poetic indictment of the War on Drugs that LSD, the first synthetic psychedelic, demonized for decades and the target of extremely expensive law enforcement operations, looks to be far safer than its replacements.

—Earth and Fire Erowid, in Erowid Extracts

It is called 25I-NBOMe, or 2C-I-NBOMe, or SC-B-NBOMe, or, erroneously, 2C-I. It belongs to a group of drugs called the NBOMes, which are derived from phenethylamine-based drug families made infamous by Dr. Alexander Shulgin. The NBOMe part stands for N-Benzyl-Oxy-Methyl. After it was first synthesized in 2003, Purdue University did some research on the chemical structure of NBOMes, but it was not until 2010 that the drugs began to appear in the underground market.  25I-NBOMe, the most common variety, is strongly psychedelic, with vivid visual and sensory effects. It can also cause horrid trips, especially at higher doses, and like LSD, it can cause vasoconstriction in the form of elevated blood pressure.

Earth and Fire Erowid, editors of the well-regarded Erowid drug information site, wrote a special report on the NBOMes for the July Erowid Extracts.  It is worth going over in some detail.

The NBOMes were initially freebase powders, either snorted or held in the mouth, but the authors note that there is still confusion and uncertainty about the relative effectiveness of various forms of administration. In one case noted by Erowid, three friends obtained a bottle of 25-I-NBOMe, marked as 500 micrograms per drop. “Those who took one drop enjoyed the experience,” but one of the friends, “after three drops, became incoherent and frantic, then ran from the house and drove off in his car. He crashed into a tree and woke up in the hospital two days later….”

This suggests both high potency and a rapid ramp-up of negative effects with dosage, making the NBOMes generally unreliable as street drugs. As the article in Erowid Extracts notes, “The unusually high potency makes overdoses more likely. Unfortunately, the risks of 25I (and perhaps other NBOMes) at high doses seem to include delirious, dangerous behavior (with some accidents resulting in death), as well as the possibility of death from direct pharmacological effects. Medically dangerous doses may be as low as 3-5 mg.”

Even worse, 25I and 25C, when sold as powders, makes dosing even more precarious. Drugs this strong in powder form should only be handled by someone wearing Walter White-style hand and eye protection. “Many people have prior experience with insufflating small lines or bumps of a psychedelic or stimulant,” says Erowid. “It’s a fairly new phenomenon that a similarly-sized line of a drug could lead to death.”

On another note, the incredible potency of the NBOMes makes them imminently smuggleable. A single 750-mcg dose equals about 6 grains of table salt. You could hide about 100,000 doses of 25I in a soda pop can.

For historical perspective, the authors point to the DEA’s bust-up of global supply chains for LSD in the early 2000s. Figures from the Monitoring the Future survey show that use of LSD by 18 year-olds has gone from about 8% in 1999 to less than 2% by 2009. What to do with all that perforated blotter paper? One time-honored response from dealers is to dump a different chemical on the paper and sell it as LSD. Erowid reminds us that LSD sold as the more expensive and difficult-to-synthesize mescaline in the hippie heydays was an early example of this practice.  As one Erowid contributor put it, “Which do you think would sell better, blotter sold as ‘25I-NBOMe’ or blotter sold as the now nearly mythical ‘acid’?”

Erowid found that at the online drug  site Silk Road, NBOMes were being offered at prices 5 to 10 times cheaper than LSD. Silk Road sells 25B-NBOMe powder for between $90 and $200 a gram. Hit size is often 1 mg or more, which is definitely a large dose. Vendors at Silk Road also sell perforated blotter paper with classic acid blotter designs from the past, like Albert Hofmann and the Beatle’s Yellow Submarine.

All of this adds up to erroneous reports of death by LSD, amid actual overdoses caused by an incredibly powerful and relatively untested new drug with a murky track record. Acid is not a lethal drug, and no deaths by overdose have ever been clearly and directly attributed to LSD.

The state of Virginia banned the NBOMes last year, and so far this year, several other states and nations have joined in. But Erowid points out that the U.N.’s World Drug Report 2013 concluded that “no sooner is one substance scheduled, than another one replaces it, thus making it difficult to study the long-term impact of a substance on usage and its health effects.” All of which, says Erowid, begs the question of what drugs will pop up to replace 25I-NBOMe once it is banned? Erowid has high hopes for a landmark New Zealand bill calling for a vendor framework in which the drugs are sold legally only if registration, safety testing, and recordkeeping meet certain standards. The bill is expected to become law in New Zealand later this year.

As Erowid notes, other countries will be watching New Zealand closely. A report by the Health Officers Council of British Columbia points out that “Prohibiting a substance does send a message of social disapproval of use… but the value of using prohibition to send a message to dissuade use must be weighed against the harmful consequences of implementing prohibition….”

Photo Credit:  http://ewsd.wiv-isp.be 

Sunday, April 1, 2012

Interview with Cognitive Neuropsychologist Keith Laws


LSD, E, CBT, and “Mind-Pops.”

Our latest participant in the “Five Question Interview” series is Dr. Keith Laws, professor of cognitive neuropsychology and head of research in the School of Psychology at the University of Hertfordshire, UK. Dr. Laws holds a Ph.D. from the Department of Experimental Psychology at the University of Cambridge, and is the author of Category-Specificity: Evidence for Modularity of Mind. He has written extensively on cognitive deficits resulting from certain types of neurological injury, and has won several awards for his research on cognitive functioning in schizophrenia. He also maintains an active interest in the challenges of functional brain imaging. Professor Laws is frequently quoted in the British media, and is the author of more than 100 peer-reviewed articles. He is a Chartered Psychologist and an Associate Fellow of the British Psychological Society. And recently, Professor Laws became a blogger, launching the LawsNeuroBlog. He maintains a web homepage, and is virtually unbeatable in the category of obscure British rock trivia.


1. LSD is back in the news, with a rehash of several old studies on acid and alcoholism. A lot of people would like to revive research interest in LSD, MDMA, magic mushrooms, and other psychedelics. What’s your view?

Keith Laws: Yes, “re-hash” is an appropriate phrase—we are witnessing a rebranding of “counter-culture” as “over-the-counter-culture.” The history of LSD research is frequently retold as if grand therapeutic advances were halted because hostile governments criminalised LSD. The bottom-line, however, is that most studies of the 50s and 60s produced little worthy of further scientific pursuit. The recent meta-analysis of 60s studies examining whether LSD reduces “alcohol misuse” is a case in point.

That meta-analysis consisted of 6 trials—none of which produced a significant effect, but their total pooled effect suggested some impact on alcohol misuse. In my recent post on this study, I highlighted a series of points, including: how it is likely that further negative studies have been gathering dust in the file drawers of researchers over the years; how some samples consisted of people with serious comorbid mental health and neurological problems (schizophrenia, epilepsy, organic brain disorder, low IQ); and crucially, how the authors made the totally unfounded assumption that anyone dropping-out of the studies had relapsed into drinking. This had a large and disproportionate impact on the control samples in those studies—as many more dropped out from control groups. Combined with the lack of significant effects in any one study, doubts exist about relying on these data as a justification for starting large-scale trials of LSD for alcoholism. We should certainly skeptically regard statements by some, such as Professor David Nutt, that LSD is “as good as anything we’ve got for treating alcoholism.”

2. Tell us about your research interest in the effect of Ecstasy (MDMA) on memory.

Keith Laws: First, I think its crucial not to confuse E and MDMA. Studies of MDMA in humans are few, and mostly examine acute effects via self-report. The vast majority of studies though, including our work, examine the residual effects of street-E in abstinent users i.e. taking largely unknown compounds mixed with varying degrees of MDMA. For me, the real public health issue relates to street-E since most people outside of the lab rarely get to consume pure MDMA.

In 2007 we meta-analysed 26 studies that had examined memory on standardized tests in over 600 ecstasy users and 600 non-users and found significant long and short-term verbal memory impairments in 75% of users. Intriguingly, E was unrelated to visual memory problems; however those who also smoked cannabis did display significant visual memory impairment. A key finding of ours was that the lifetime number of E tablets consumed was unrelated to the degree of memory impairment. This led to a host of misrepresentations in the media and amongst E users who saw it as license to take as many Es as they want. I view this finding, however in a much starker light—taking E is akin to playing Russian Roulette with your memory. Some may tolerate 100s or even 1000s of E tablets, but for others far fewer may lead to memory problems—we can predict that 3 in 4 users will develop memory problems, but not which 3 or after how many tablets. Of course, ecstasy (like Cannabis) is often advocated as a safe-ish drug because it rarely kills. Indeed, metrics of drug harm developed in the UK emphasise physical and social harm, but fail to explicitly acknowledge the cognitive problems associated with E and other recreational drugs. Given that as many as 500,000 young people in the UK use E each week and 75% are affected, then that’s 375,000 young people developing significant verbal memory problems!

3. You’re not convinced by the findings of a recent study of magic mushrooms, where the researchers documented an overall decrease in brain activity. What else could account for this effect?

Keith Laws: Well, the surprising thing about the Carhart-Harris et. al. psilocybin study was the general pattern of brain deactivation, which contrasts with the findings of activation in others such as Vollenweider and colleagues in Switzerland who find increased activation. The decreased activation especially in the medial prefrontal cortex (mPFC) and the posterior cingulate cortex (PCC) were curious and reminded me of the similar deactivation in these areas linked both to anxiety and to the anticipation of unpleasant events. It occurred to me that the prospect of tripping in a scanner may be quite anxiety provoking, and several features of the study led to me to think this may have been the case. First the order of testing was always the same - participants received the placebo scan always before the psilocybin scan and so, could always anticipate the trip— potentially heightening anxious anticipation in that condition. Second, Carhart-Harris et. al. measured “anxiety” and “fear of losing one’s mind” and both multiplied many fold in the psilocybin condition. Interestingly and subsequently, Vollenweider and colleagues pooled date from 23 studies and found that experimental settings involving scanning most strongly predicted unpleasant and/or anxious reactions to psilocybin - converging directly on my suspicion. Although nobody would deny that hallucinogens such as psilocybin impact brain function - the question is which parts reflect the “trip” and which parts reflect “anxiety about the trip”?

4. You have also looked at the matter of using cognitive behavioral therapy for various kinds of mental disorders. How does CBT measure up, in your opinion? Is it useful for addiction?

Keith Laws: Yes, unlike any other country, the UK endorses using CBT to treat psychotic symptoms and to prevent relapse in schizophrenia. Indeed, “NICE” (the National Institute of Clinical Excellence), which decide which treatments are made available to UK patients, suggest that we offer CBT to “all people with schizophrenia”. Anyway, we meta-analysed the data for whether CBT reduces symptomatology or prevents relapse and came to the conclusion that the evidence supports neither. Crucially, CBT only appeared to “work” when the therapists were not blind at outcome assessment i.e. they knew to which group the patient was assigned (CBT or control)! The irony is that CBT therapists sing the mantra of evidence-based practice!

In terms of the use of CBT in people with substance abuse problems, it produces a small impact on abstinence with opiates, stimulants and cocaine, but has little or impact on alcohol use; and as one might expect, these effects disappear across time. Some evidence also suggests that women respond better to CBT than men. Perhaps the most intriguing finding in this area is that CBT has had much greater success in reducing cannabis use, with up to 80% showing significant reduction in use.

5. What else have you been investigating recently? What are you excited about?

Keith Laws: Over the past 3 years or so I have been doing more work with individuals suffering from the obsessive compulsive syndrome of disorders i.e. OCD, Body Dysmorphic Disorder, Trichotillomania, Schizo-Obsessive disorder, Tourette’s, and Perfectionism. Our work is looking at phenotypes that might be expressed through this range of disorders and in their first-degree unaffected relatives. 

Other things we are working on include what we call “Mind-Pops”—those little thoughts, words, images, or tunes that suddenly pop into your mind at unexpected times and are totally unrelated to your current activity—described long ago by novelists such as Marcel Proust and Vladimir Nabokov.  We have just published a paper showing that verbal hallucinations, the core symptom of schizophrenia, may be related to the mind-pop phenomenon that almost everybody experiences, but just manifests itself in a different way.

Friday, March 16, 2012

LSD and Alcohol: The History


Back when acid was legal.

After last week’s blitz of coverage concerning studies done in the 60s on the use of LSD for the treatment of alcoholism, I thought it would be useful to provide a bit of background; some pertinent psychedelic history to help put this information in perspective:

It may come as a surprise to many people that throughout the 60s, there were LSD clinics operating in England and Europe. European LSD therapists tended to use very low doses as an adjunct to traditional psychoanalytic techniques. But North American researchers took a different, bolder approach. When “psychedelic” therapy began to catch on in Canada and the United States, therapists typically gave patients only one or two sessions at very high doses. These early efforts were aimed at producing spontaneous breakthroughs or recoveries in alcoholics through some manner of religious epiphany or inner conversion experience. The only other quasi-medical approach of the day, the Schick Treatment Center’s brand of “aversion therapy,” was not seen to produce very compelling long-term recovery rates, and subsequently fell out of favor. In this light, the early successes with LSD therapy, sometimes claimed to be in the 50-75 per cent range, looked noteworthy indeed. However, the design and criteria of the LSD/alcoholism studies varied so widely that it has never been possible to draw definitive conclusions about the work that was done, except to say that LSD therapy seemed to be strikingly effective for certain alcoholics. Some patients were claiming that two or three trips on LSD were worth years of conventional psychotherapy—a claim not heard again until the advent of Prozac thirty years later.

 “I’ve taken lysergic acid several times, and have collected considerable information about it,” Bill Wilson, the co-founder of Alcoholics Anonymous, disclosed in a private letter written in 1958. “At the moment, it can only be used for research purposes. It would certainly be a huge misfortune if it ever got loose in the general public without a careful preparation as to what the drug is and what the meaning of its effects may be.”  Like many others, Wilson was excited by LSD’s potential as a treatment for chronic alcoholism. Even Hollywood was hip to the new therapy. Cary Grant, among others, took LSD under psychiatric supervision and pronounced it immensely helpful as a tool for psychological insight. Andre Previn, Jack Nicholson, and James Coburn agreed. (It could be argued that the human potential movement began here).

No drug this powerful and strange, if American history was any guide, could remain legal for long. Unlike their colleagues in the intelligence agencies, politicians and law enforcement officers didn’t know about Mongolian shamans and their fly agaric mushrooms; about European witches and their use of psychoactive plant drugs like nightshade and henbane; about Persian sheiks with their cannabis water pipes; Latin American brujos with their magic vines.

But for the CIA, the big fish was always LSD.

What interested the Central Intelligence Agency about LSD was its apparent ability to produce the symptoms of acute psychosis. Operation ARTICHOKE was designed to ferret out LSD’s usefulness as an instrument of psychological torture, and as a possible means of destabilizing enemy forces by means of aerosol sprays or contaminated water supplies. (The drug’s overwhelming potency made such parts-per-billion fantasies a possibility.)

The agency knew where to turn for a secure American source of supply. Eli Lilly and Co., the giant drug manufacturer, was already involved in LSD research on behalf of the U.S. government. The trouble was that LSD was expensive, and all roads led to Sandoz Laboratories in Switzerland. Organic LSD had to be painstakingly extracted from ergot, a fungus that grows in kernels of rye. Eventually, Sandoz and Eli Lilly successfully synthesized LSD in their own laboratories. With the advent of a reliable domestic supplier of synthetic LSD, the CIA under Allen Dulles was assured of a steady source for experimental purposes.

When LSD did not pan out as a reliable agent of interrogation, CIA investigators turned their attention to its purported ability to mimic acute psychosis—its “psychomimetic” aspect—which researchers were praising as a new avenue toward a biological understanding of schizophrenia. The CIA funneled grant money for LSD research into the academic and commercial R&D world through a host of conduits. Various experiments with non-consenting subjects—typically military or prison personnel—showed that LSD could sometimes break down established patterns of thought, creating a “twilight zone” during which the mind was more susceptible to various forms of psychological coercion and control. Perhaps, under the influence of LSD, prisoners could be transformed into counter-espionage agents. It also occurred to the CIA that the same drug could be used on their own agents for the same purposes. Numerous CIA agents took LSD trips in order to familiarize them with acid’s Alice-in-Wonderland terrain. Some of these unusual experiments were captured on film for use in military training videos.

One place where ARTICHOKE research took place was the Addiction Research Centre at the Public Health Service Hospital in Lexington, Kentucky—the same hospital that specialized in the treatment of hardcore heroin addicts. Lexington was part hospital and part penitentiary, which made it perfect for human experimentation. The addict/inmates of Lexington were sometimes given LSD without their consent, a practice also conducted at the federal prison in Atlanta, and at the Bordentown Reformatory in New Jersey. 

In 1953, then-CIA director Allen Dulles authorized Operation MK-ULTRA, which superseded earlier clandestine drug investigations. Under the direction of Dr. Sidney Gottlieb, a chemist, the government began slipping LSD and other psychoactive drugs to unwitting military personnel. During a work retreat in Maryland that year, technicians from both the Army and the CIA were dosed without their knowledge, and were later told that they had ingested a mind-altering drug. Dr. Frank Olson, a civilian biochemist involved in research on biological warfare, wandered away from the gathering in a confused state, and committed suicide a few days later by leaping to his death from an upper floor of the Statler Hilton in New York City. The truth about Olson’s death was kept secret from his family, and from the rest of the nation, for more than twenty years. In 1966, LSD was added to the federal schedule of controlled substances, in the same category as heroin and amphetamine. Simple possession became a felony. The Feds had turned off the spigot, and the research came to a halt. Federal drug enforcement agents began showing up at the homes and offices of well-known West Coast therapists, demanding the surrender of all stockpiles of LSD-25. The original acid elite was being hounded, harassed, and threatened in a rancid atmosphere of pharmaceutical McCarthyism. Aldous Huxley, Humphrey Osmond, even father figure Albert Hoffman, all viewed these American developments with dismay. The carefully refined parameters and preparations, the attention to set and setting, the concerns over dosage, had gone out the window, replaced by a massive, uncontrolled experiment in the streets. Small wonder, then, that the circus atmosphere of the Haight-Ashbury “Summer of Love” in 1967 seemed so badly timed. Countercultural figures were extolling the virtues of LSD for the masses—not just for research, not just for therapy, not as part of some ancient religious ritual—but also just for the freewheeling American hell of it. What could be more democratic than the act of liberating the most powerful mind-altering drug known to man?

It is at least conceivable that researchers and clinicians eventually would have backed away from LSD anyway, on the grounds that the drug’s effects were simply too weird and unpredictable to conform to the rigorous dictates of clinical studies. Nonetheless, researchers had been given a glimpse down a long, strange tunnel, before federal authorities put an end to the research.


Graphics Credit: http://news.sky.com

Saturday, August 6, 2011

The Original Magic Bus: A Preview


Ken Kesey and His Merry Band of Pranksters Search for a Cool Place

"In 1964, Ken Kesey, the famed author of "One Flew Over the Cuckoo's Nest," set off on a legendary, LSD-fuelled cross-country road trip to the New York World's Fair. He was joined by "The Merry Band of Pranksters," a renegade group of counterculture truth-seekers, including Neal Cassady, the American icon immortalized in Kerouac's "On the Road," and the driver and painter of the psychedelic Magic Bus. Kesey and the Pranksters intended to make a documentary about their trip, shooting footage on 16MM, but the film was never finished and the footage has remained virtually unseen. With Magic Trip, Oscar-winning director Alex Gibney and Alison Ellwood were given unprecedented access to this raw footage by the Kesey family. They worked with the Film Foundation, HISTORY and the UCLA Film Archives to restore over 100 hours of film and audiotape, and have shaped an invaluable document of this extraordinary piece of American history."
--(C) Magnolia Pictures

Here's a preview of Magic Trip:

Photo Credit: http://www.key-z.com

Tuesday, April 19, 2011

So, Like, We’re Watching the LSD Episode of The Fringe...


Lysergic Acid Diethylamide

So this guy I know? Like really, really well? He’s over at my place and we’re watching The Fringe on TV and smoking a bowl, excuse me, we’re vaping a bowl, he’s an older guy and all concerned with his health and shit. So we’re watching the Lysergic Acid Diethylamide episode of The Fringe, and Walter’s rapping away like a drunken monkey as usual, and they’re hardly underway before my friend is jumping up off the couch and saying no, that’s not what LSD was like…. I said how would I know, and anyway the clothes in those Sixties photos always looked so bad, they must have looked even worse when you were tripping on that stuff. The closest thing I’ve ever had to a psychedelic experience was that time that guy slipped a roofie in my Mimosa. But I digress. My friend says no, no, see, when you took acid, you didn’t suddenly get hurled into somebody else’s consciousness, which in this case seems to resemble some crowded city out of Inception, with your tripping buddy perched on a bus, waving at you. That’s just not fucking how it went. So then he pauses, gets kind of sheepish, says, well, actually, that did happen once, but that’s not the point. And then blah blah happened. And everybody could read everybody else’s mind. And from then on everything was blah blah blah. And peace reigned forevermore. Okay, that’s not fair, he’s really just complaining that they aren’t telling it straight, about how LSD really feels, and what you really see and shit. This notion about taking drugs and ending up in cities full of people wearing black clothing really cracked him up. So I go, when was the last time you took a walk down Lake Street and saw somebody wearing some other color? But he loved the black guy who accidentally dosed himself and then started comparing his stick of red licorice to Bernini's spiral altar at St. Peter's. But car chases? Elevators? The Twin Towers, for God’s sake? Where are the colors, the tracers, the melting edges, the fractal glow of a universe in constant motion? Or something like that. My friend wants to know how they thought they were going to get away with it. Turning it all into a cartoon. And not just any cartoon, but that awful rotoscoping shit that made him seasick when we rented “A Scanner Darkly.”  Like they thought nobody who had ever taken the stuff was going to watch their crappy show, anyway? Whatever. But I thought that last part was cool, the cartoon guys were running to catch a giant purple blimp, like an episode of the Teenage Mutant Ninja Turtles—and chased by zombies!  And more car chases! Too cool! And my friend is laughing, and then he says yeah, well, something like that happened to him once, too….

Photo Credit:http://clatl.com/

Thursday, March 24, 2011

LSD Flashbacks


Evidence for “hallucinogen persisting perception disorder.”

After taking a dose of mescaline in 1898, the writer Havelock Ellis reported that he experienced a heightened sensitization to “the more delicate phenomena of light and shade and color” for a prolonged period after his drug experience. John H. Halpern and Harrison Pope of the Alcohol and Drug Abuse Research Center at Harvard Medical School think that the published report of his experience may represent the first description of what came to be known as a hallucinogenic “flashback.”

In “Hallucinogen persisting perception disorder: what do we know after 50 years?” authors John Halpern and Harrison Pope, Jr. make a distinction between HPPD, as it’s known for short, and the common term, “flashback.” Writing in Drug and Alcohol Dependence, the Harvard Medical School researchers concluded that “the term ‘flashback’ has been defined in so many ways that it has become virtually useless.” A flashback typically refers to a short-lived, transient, and generally benign re-experiencing of perceptual changes that accompanied hallucinogenic drug use. Hallucinogen persisting perception disorder, on the other hand, includes this re-experiencing of visual symptoms--but also results in anxiety and distress. No anxiety, no HPPD. Without that diagnostic element, you have only your garden-variety acid flashback.

Halpern and Pope collected available reports of the phenomenon, most of which were anecdotal, and at least 20 years old. Most, but not all, involved LSD. What manner of visual alterations are we talking about? Halpern and Pope list such symptoms as “geometric hallucinations, false perceptions of movement in the peripheral visual fields, flashes of color, intensified colors, trails of images of moving objects, positive after images, halos around objects,” and objects appearing larger or smaller than they actually are.

Problems of diagnosis abound. Various conditions and substances can present symptoms that sometimes mimic the symptoms of HPPD—epilepsy, migraine, certain neurological conditions, hysteria, other drugs, schizophrenia, and some mood disorders. Also, “perceptual phenomena should be sufficiently striking to be outside the range of normal experience.” Seeing bright spots in front of your eyes when you enter a dark room doesn’t count, for example.

The authors note similarities between the anxiety caused by hallucinogen persisting perception disorder and posttraumatic stress disorder (PTSD):  “Several investigators have published theoretical articles surmising that ‘flashbacks’ reflect lasting memories from the unusually distinct and powerfully emotional experiences induced under hallucinogen intoxication.”  In the case of LSD, the classic “bad trip” qualifies in this respect. Curiously, the authors found that “individuals administered LSD in therapeutic or research settings are far less likely to develop HPPD than individuals using LSD illicitly.” Moreover, a study of 500 members of the Native American Church, who had taken peyote more than 100 times, found no evidence of HPPD in that group.

Despite the diagnostic uncertainties, and the rarity of the condition, “it seems inescapable that at least some individuals who have used LSD, in particular, experience persistent perceptual abnormalities reminiscent of acute intoxication” that cannot be better explained by other conditions, and which last for weeks or months after the last exposure to hallucinogens.

Some researchers believe that persistent flashbacks are due to “disinhibition of visual processing related to a loss of serotonin receptors on inhibitory interneurons.” Which is one way of suggesting that HPPD might represent neural damage in some cases. Others see some form of neurological “kindling” effect that ignites a replay of visual effects.  In either case, one would expect to see higher rates of HPPD in heavy users, compared to more casual users—but this does not appear to be the case.

In an interview published at NeuroSoup.com, Dr. Halpern said that people suffering from HPPD seem to be photosensitive—light acts as a trigger for the reactivation of the symptoms. Halpern proposed a theory that “there is probably something different in the visual cortex of these individuals that pre-date use of an hallucinogen…. people will describe seeing ‘floaters’ in their field of vision as a child and/or that they had visual disturbances that also predated first use of a hallucinogen. So, while there may be something about LSD and HPPD, there may also be some things that are unique to this population of users, as well.”

Halpern notes that prescribing antipsychotics for HPPD “is usually not necessary or a good choice.”  And there are no confirmatory tests for the condition. He believes that the best medicine for troubling flashbacks is “reassurance.” The symptoms typically resolve without treatment within a few months for most people who seek medical attention for flashbacks. Also, this tip: “My favorite treatment is a simple pair of sunglasses. Most people with HPPD describe symptom activation or maddeningly increased intensity of symptoms when they are in bright light… Sunglasses definitely are helpful.”

Photo Credit: http://www.derandereblickwinkel.de

Tuesday, May 18, 2010

Al Hubbard, the Johnny Appleseed of LSD


“The Original Capt. Trips.”

The scientists, therapists, and artists who experimented with LSD therapy in the late 1950s were not prepared for the likes of Timothy Leary, novelist Ken Kesey, poet Allen Ginsberg, and the assorted freaks, pranksters, con artists and runaways of the Woodstock Generation. Ken Kesey, in particular, delighted in stinging the Feds by insisting that it was Uncle Sam who first got him high, paying Kesey and others to take LSD, guinea pig-style, in certain government-funded research programs in Palo Alto and at Stanford University in the early 1960s.

It made a great story, and it happened to be true. However, the original chapter of the acid story began ten years earlier, when a former intelligence agent, rogue businessman, and general intellectual gadfly named Al Hubbard took his first LSD trip. Captain Alfred M. Hubbard, who has been dubbed the “Original Capt. Trips,” was part of a select cadre of World War II veterans who had been involved in creating intelligence institutions like the Office of Strategic Services and the CIA, and who had immersed themselves in cryptology and truth serums and interrogation drugs in the service of the war effort. (Thomas Pynchon caricatured some of this work in his novel, Gravity’s Rainbow.) Hubbard broke ranks with the intelligence community early on, but continued to share his clandestine stash of LSD with certain friends and acquaintances. This odd and extraordinary businessman is said to have arranged private LSD sessions in the late 1950s for scientists, captains of industry, members of the British parliament, UN representatives, prime ministers, and various artists. For a time, Al Hubbard settled in Vancouver, where he became Canada’s only legally licensed, FDA-approved importer of Sandoz LSD. In certain North American research circles, Al became a very popular man.

Hubbard is credited by various parties with being the man who put together the basics of the North American psychedelic therapy sessions and hippie acid tests to come—high doses of LSD, amplified music, strobe lights, and experiments with ESP. Along with Huxley, Hubbard came to believe that the more mystical or “transpersonal” experiences LSD sometimes afforded might hold considerable psychotherapeutic potential. With LSD provided by Hubbard, Canadians Abram Hoffer, Ross Mclean, and Humphrey Osmond pursued the idea of LSD as a treatment for alcoholism. In the U.S, research on LSD and alcoholism was undertaken by Oscar Janiger, Sanford Unger, and others on the West Coast.

Throughout this period, there were LSD clinics operating in England and Europe. European LSD therapists tended to use very low doses as an adjunct to traditional psychoanalytic techniques. But North American researchers took a different, bolder approach. When “psychedelic” therapy began to catch on in Canada and the United States, therapists typically gave patients only one or two sessions at very high doses. These early efforts were aimed at producing spontaneous breakthroughs or recoveries in alcoholics through some manner of religious epiphany or inner conversion experience. The only other quasi-medical approach of the day, the Schick Treatment Center’s brand of “aversion therapy,” was not seen to produce very compelling long-term recovery rates, and subsequently fell out of favor.

In this light, the early successes with LSD therapy, sometimes claimed to be in the 50-75 per cent range, looked noteworthy indeed. However, the design and criteria of the LSD/alcoholism studies varied so widely that it has never been possible to draw definitive conclusions about the work that was done, except to say that LSD therapy seemed to be strikingly effective for certain alcoholics. Some patients were claiming that two or three trips on LSD were worth years of conventional psychotherapy—a claim not heard again until the advent of Prozac thirty years later.

Adapted from The Chemical Carousel: What Science Tells Us About Beating Addiction by Dirk Hanson © 2008, 2009.

Tuesday, August 12, 2008

Clinical LSD


Psychedelic psychotherapy” makes a comeback.



“Take a tab of Sunshine and call me in the morning.”

No, we haven’t reached that point yet. But there is a growing movement among research scientists to take another look at powerfully psychoactive drugs like LSD, psilocybin, MDMA and ibogaine as treatments for a variety of illnesses.

In June, the first clinical trial of LSD since the 1970s began in Switzerland, according to the U.K. Guardian. While LSD has sparked renewed interest as a potential treatment for everything from depression to cluster headaches to post-traumatic stress disorder, the Swiss trial will focus on administering LSD in varying doses to eight terminally ill subjects. “During the course of therapy,” the Guardian reported, “researchers will assess the patients’ anxiety levels, quality of life and pain levels.”

“The working hypothesis is that if psilocybin or LSD can occasion these experiences of great personal meaning and spiritual significance,” said Professor Roland Griffiths of the Johns Hopkins School of Medicine in Baltimore, “then it would allow [terminal patients] hopefully to face their own demise completely differently—to restructure some of the psychological angst that so often occurs concurrently with severe disease.”

Griffiths recently conducted a study of the effects of psilocybin on 36 health adult volunteers, the results of which were published in the British Journal of Psychopharmacology. “When administered under supportive conditions,” Griffiths concluded, “psilocybin occasioned experiences similar to spontaneously occurring mystical experiences that, at 14-month follow-up, were considered by volunteers to be among the most personally meaningful and spiritually significant of their lives.”

Griffiths told the Guardian that drugs classed as hallucinogenic had become thoroughly demonized after the excesses of the 1960s. “As a culture we just decided clinical research shouldn’t be done with this class of compounds,” he commented. “This was partly the federal regulatory authorities, it was partly the funding agencies and it was partly the academics themselves—Leary had so discredited a scientific approach to studying these compounds that anyone who expressed an interest in doing so was automatically discredited.”

The Journal of Psychopharmacology recently published a training manual for the use of investigators who are currently studying the effects of such drugs. According to the manual, psychedelic drugs are relatively safe when administered at the proper dose by a trained medical professional. The drugs are non-toxic, non-addictive, and, except in rare cases, do not cause long-lasting psychoses.

A paper in the same journal by B. Sessa of the Psychopharmacology Unit, Bristol University, concluded:

“There are similarities between the typical traits of creative people and the subjective psychological characteristics of the psychedelic (hallucinogenic) drug experience. This phenomenon was studied in a number of small trials and case studies in the 1960s. Results were inconclusive, and the quality of these studies – by modern research standards – was merely anecdotal. Nevertheless, with today’s current renaissance in psychedelic drug research and the growing interest in cognitive enhancing drugs, now may be the time to re-visit these studies with contemporary research methods.”

In the U.S., psychology professor Charles Grob of the Harbor-UCLA Medical Centre also recently completed a clinical trial using psilocybin to treat terminally ill cancer patients.

Graphics Credit: www.rsc.org

Sunday, February 10, 2008

LSD and Serotonin


Early psychedelic research on alcoholism.

What did LSD do to the brain, exactly, in order to set off the fireworks that so fascinated brain scientists, hippies, and government spies? And why, after years of massive, unauthorized field-testing, so to speak, was there so little evidence implicating LSD as an addictive drug? Powerful as it was, LSD did not show any of the classic attributes of addiction, such as withdrawal or craving, although it was possible to build up a tolerance to its effects with repeated dosings.

Another novel brain chemical, discovered less than a year after Albert Hofmann's discovery of LSD, proved to be a crucial piece of the puzzle.

According to an early theory, the aberrant mental functioning produced by the tiniest dose of LSD was due to interference with normal levels of serotonin in the brain. In 1954, chemists D.W. Woolley and E. Shaw had published an article in Science strongly arguing that serotonin was the likely biochemical basis for major mental disorders. Wooley and Shaw confirmed that the most acutely serotonin-active substance known to man was the ergot derivative known as LSD. LSD’s chemical architecture looked eerily similar to that of serotonin.

While the idea of LSD as a “model” of psychosis did not hold up, the link between serotonin and mental disorders was there all along. The strongly serotonin-mediated mental disorders, researchers ultimately discovered, were depression, drug addiction, and alcoholism.

The psychedelic drugs, new and old, are not only among the most powerful ever discovered, but are also tremendously difficult to study and utilize responsibly. Nonetheless, these drugs have always played an important part of the story, even though they are not addictive. LSD, mescaline, DMT, psilocybin, Ibogaine, ayahuasca—none of these appeal to lab rats as a drug of abuse.

Psychedelics have been exhorted, and occasionally deployed, as specific anti-craving medications for more than 50 years now. The psychedelic experience seems to assist some addicts in their efforts to remain sober and abstinent. However, the risks of casual experimentation with these substances should be obvious. Recent research on Ecstasy only makes this point more emphatically.

In the 1950s, along with Aldous Huxley and others, Al Hubbard came to believe that the more mystical or “transpersonal” experiences LSD sometimes afforded might hold considerable psychotherapeutic potential. With LSD provided by Hubbard, Canadians Abram Hoffer, Ross Mclean, and Humphrey Osmond pursued the idea of LSD as a treatment for alcoholism. In the U.S, Oscar Janiger, Sanford Unger, and others undertook research on LSD and alcoholism on the West Coast.

Throughout this period, there were LSD clinics operating in England and Europe. European LSD therapists tended to use very low doses as an adjunct to traditional psychoanalytic techniques. But North American researchers took a different, bolder approach. When “psychedelic” therapy began to catch on in Canada and the United States, therapists typically gave patients only one or two sessions at very high doses. These early efforts were aimed at producing spontaneous breakthroughs or recoveries in alcoholics through some manner of religious epiphany or inner conversion experience. The only other quasi-medical approach of the day, the Schick Treatment Center’s brand of “aversion therapy,” was not seen to produce very compelling long-term recovery rates, and subsequently fell out of favor.

In this light, the early successes with LSD therapy, sometimes claimed to be in the 50-75 per cent range, looked noteworthy indeed. However, the design and criteria of the LSD/alcoholism studies varied so widely that it has never been possible to draw definitive conclusions about the work that was done, except to say that LSD therapy seemed to be strikingly effective for certain alcoholics. Some patients were claiming that two or three trips on LSD were worth years of conventional psychotherapy—a claim not heard again until the advent of Prozac thirty years later.

“I’ve taken lysergic acid several times, and have collected considerable information about it,” Bill Wilson, the co-founder of Alcoholics Anonymous, disclosed in a private letter written in 1958. “At the moment, it can only be used for research purposes. It would certainly be a huge misfortune if it ever got loose in the general public without a careful preparation as to what the drug is and what the meaning of its effects may be.” Like many others, Wilson was excited by LSD’s potential as a treatment for chronic alcoholism. Even Hollywood was hip to the new therapy. Cary Grant, among others, took LSD under psychiatric supervision and pronounced it immensely helpful as a tool for psychological insight. Andre Previn, Jack Nicholson, and James Coburn agreed. (It could be argued that the human potential movement began here).

But the early addiction research was stuck in an impossible situation. Some of the best tools available to scientists for studying the workings of the human brain were the very drugs that were increasingly prohibited under state and federal law--drugs like heroin, cocaine, PCP, LSD, and marijuana.

By the early 1970s, meaningful research involving any of these substances had virtually ground to a halt, and grants for clinical work had dried up completely.

--Excerpted from The Chemical Carousel: What Science Tells Us About Beating Addiction © Dirk Hanson 2008, 2009.


Photo Credit: Albert Hofmann Foundation

Related posts: Ibogaine and Addiction

Serotonin and Dopamine: A Primer

Digg!


Related Posts Plugin for WordPress, Blogger...